| Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. | |
| | |
MedLine Citation:
|
PMID: 23045592 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral therapy, standard therapy is still poorly defined. This prospective study investigates a stage- and risk-adapted treatment strategy in patients with HIV-HL. PATIENTS AND METHODS: Patients with early favorable HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of involved-field (IF) radiation. In patients with early unfavorable HIV-HL, four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP baseline) or four cycles of ABVD + 30 Gy of IF radiation were administered. Six to eight cycles of BEACOPP baseline were given in patients with advanced-stage HIV-HL. In patients with advanced HIV infection, BEACOPP was replaced with ABVD. RESULTS: Of 108 patients (including eight female patients) included in the study, 23 (21%) had early favorable HL, 14 (13%) had early unfavorable HL, and 71 (66%) had advanced-stage HL. The median CD4 count at HL diagnosis was 240/μL. The complete remission rates for patients with early favorable, early unfavorable, and advanced-stage HL were 96%, 100%, and 86%, respectively. The 2-year progression-free survival of the entire study population was 91.7%. Eleven patients (11%) have died, and treatment-related mortality was 5.6%. The 2-year overall survival rate was 90.7% with no significant difference between early favorable (95.7%), early unfavorable (100%), and advanced-stage HL (86.8%). CONCLUSION: In patients with HIV-HL, stage- and risk-adapted treatment is feasible and effective. The prognosis for patients with HIV-HL may approach that of HIV-negative patients with HL. |
| | |
Authors:
|
Marcus Hentrich; Marcel Berger; Christoph Wyen; Jan Siehl; Jürgen K Rockstroh; Markus Müller; Gerd Fätkenheuer; Elisabeth Seidel; Maike Nickelsen; Timo Wolf; Ansgar Rieke; Dirk Schürmann; Ralf Schmidmaier; Manfred Planker; Jürgen Alt; Franz Mosthaf; Andreas Engert; Keikawus Arasteh; Christian Hoffmann |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2012-10-08 |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 30 ISSN: 1527-7755 ISO Abbreviation: J. Clin. Oncol. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-19 Completed Date: 2013-03-06 Revised Date: 2013-03-25 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 4117-23 Citation Subset: IM |
Affiliation:
|
Department of Hematology, Oncology and Palliative Care, Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Sanatoriumsplatz 2, 81545 Munich, Germany. marcus.hentrich@klinikum-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols / administration & dosage, adverse effects, therapeutic use* Bleomycin / administration & dosage, adverse effects Combined Modality Therapy Cyclophosphamide / administration & dosage, adverse effects Dacarbazine / administration & dosage, adverse effects Disease-Free Survival Doxorubicin / administration & dosage, adverse effects Etoposide / administration & dosage, adverse effects Female HIV Infections / complications* Hodgkin Disease / drug therapy*, pathology, radiotherapy Humans Lymphoma, AIDS-Related / drug therapy*, pathology, radiotherapy Male Middle Aged Neoplasm Staging Prednisone / administration & dosage, adverse effects Procarbazine / administration & dosage, adverse effects Prognosis Prospective Studies Remission Induction Treatment Outcome Vinblastine / administration & dosage, adverse effects Vincristine / administration & dosage, adverse effects Young Adult |
| Chemical | |
Reg. No./Substance:
|
11056-06-7/Bleomycin; 23214-92-8/Doxorubicin; 33419-42-0/Etoposide; 4342-03-4/Dacarbazine; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine; 671-16-9/Procarbazine; 865-21-4/Vinblastine |
| Comments/Corrections | |
Comment In:
|
J Clin Oncol. 2012 Nov 20;30(33):4056-8
[PMID:
23045587
]
|
Erratum In:
|
J Clin Oncol. 2012 Dec 20;30(36):4590 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mammostrat as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tam...
Next Document: Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lympho...